Get the latest Science News and Discoveries
First patient enrolled in GOG-3132/BEHOLD-Ovarian01 phase 3 study evaluating Mocertatug Rezetecan, a novel B7-H4–targeted ADC, in platinum-resistant ovarian cancer - EurekAlert!
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
None
Or read this on Eureka Alert

